Table 4 Influence of APOE genotype on AD pathology
APOE ε4 status, n (%) | p | ||
|---|---|---|---|
ε 4- | ε 4+ | ||
ABC score | |||
Not | 163 (42.9) | 10 (14.3) | < 0.001 |
Low | 191 (50.3) | 49 (70.0) | |
Intermediate/ High | 26 (6.8) | 11 (15.7) | |
Thal phase | |||
0 | 163 (42.9) | 10 (14.3) | < 0.001 |
1-2 | 112 (29.5) | 21 (30.0) | |
3 | 64 (16.8) | 25 (35.7) | |
4-5 | 41 (10.8) | 14 (20.0) | |
CAA | |||
not CAA | 289 (76.1) | 33 (47.1) | < 0.001 |
CAA | 91 (23.9) | 37 (52.9) | |
Braak stage | |||
0 − + | 208 (54.7) | 34 (48.6) | 0.203 |
I-II | 134 (35.3) | 24 (34.3) | |
>III | 38 (10.0) | 12 (17.1) | |
n | 380 (84.4) | 70 (15.6) | |